Abstract
BACKGROUND: The present analysis focuses on real-world data of Everolimus- Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years. METHODS: Data are collected from clinical records and analysed according to age cut-off (< 65 years; 65 - 69 years and [greater than or equal to] 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel- Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model. RESULTS: From July 2013 to December 2015, the EVA study enrolled overall 404 pts. 154 patients out of 404 (38,1%) were aged [greater than or equal to] 65 years, of whom 87 were [greater than or equal to] 70 years. Median duration of EVE treatment was 28.5 weeks (95% CI 19.0 - 33.8) in patients aged 65-69 years and 24,4 weeks (95% CI 19,2 - 33,2) in those aged [greater than or equal to] 70 years. Fewer patients aged 65 years received the highest EVE Dose-Intensity (> 7.5 mg/day) in comparison to younger patients (49,6% vs. 66,8%). Grade 3-4 toxicities occurred to 55 patients (35,7%), mainly stomatitis (10,9%), rash (5,8%) and non-infectious pneumonitis (NIP) (3,6%). Some toxicities, such as weight loss and anaemia were peculiarly observed in patients aged [greater than or equal to] 70 years. Five treatment-related deaths were collected (3,2%). CONCLUSIONS: EVE-EXE combination remains one of the potential treatments in HR+ patients also for elderly ones.
| Original language | English |
|---|---|
| Pages (from-to) | 31877-31887 |
| Number of pages | 11 |
| Journal | Oncotarget |
| Volume | 9 |
| Issue number | 61 |
| DOIs | |
| Publication status | Published - Aug 1 2018 |
Fingerprint
Keywords
- Advanced breast cancer
- Elderly
- Everolimus
- Exemestane
- Hormone-receptor positive
ASJC Scopus subject areas
- Oncology
Cite this
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years : New lessons for clinical practice from the EVA study. / Cazzaniga, Marina; Verusio, Claudio; Ciccarese, Mariangela; Fumagalli, Alberto; Sartori, Donata; Ancona, Cristina; Airoldi, Mario; Moretti, Gabriella; Ficorella, Corrado; Arcangeli, Valentina; Diodati, Lucrezia; Zambelli, Alberto; Febbraro, Antonio; Generali, Daniele; Pistelli, Mirco; Garrone, Ornella; Musolino, Antonino; Vici, Patrizia; Maur, Michela; Mentuccia, Lucia; La Verde, Nicla; Bianchi, Giulia; Artale, Salvatore; Blasi, Livio; Piezzo, Matilde; Atzori, Francesco; Turletti, Anna; Benedetto, Chiara; Cursano, Maria Concetta; Fabi, Alessandra; Gebbia, Vittorio; Schirone, Antonio; Palumbo, Raffaella; Ferzi, Antonella; Frassoldati, Antonio; Scavelli, Claudio; Clivio, Luca; Torri, Valter; On behalf of The EVA Study Group, behalf of The EVA Study Group.
In: Oncotarget, Vol. 9, No. 61, 01.08.2018, p. 31877-31887.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years
T2 - New lessons for clinical practice from the EVA study
AU - Cazzaniga, Marina
AU - Verusio, Claudio
AU - Ciccarese, Mariangela
AU - Fumagalli, Alberto
AU - Sartori, Donata
AU - Ancona, Cristina
AU - Airoldi, Mario
AU - Moretti, Gabriella
AU - Ficorella, Corrado
AU - Arcangeli, Valentina
AU - Diodati, Lucrezia
AU - Zambelli, Alberto
AU - Febbraro, Antonio
AU - Generali, Daniele
AU - Pistelli, Mirco
AU - Garrone, Ornella
AU - Musolino, Antonino
AU - Vici, Patrizia
AU - Maur, Michela
AU - Mentuccia, Lucia
AU - La Verde, Nicla
AU - Bianchi, Giulia
AU - Artale, Salvatore
AU - Blasi, Livio
AU - Piezzo, Matilde
AU - Atzori, Francesco
AU - Turletti, Anna
AU - Benedetto, Chiara
AU - Cursano, Maria Concetta
AU - Fabi, Alessandra
AU - Gebbia, Vittorio
AU - Schirone, Antonio
AU - Palumbo, Raffaella
AU - Ferzi, Antonella
AU - Frassoldati, Antonio
AU - Scavelli, Claudio
AU - Clivio, Luca
AU - Torri, Valter
AU - On behalf of The EVA Study Group, behalf of The EVA Study Group
PY - 2018/8/1
Y1 - 2018/8/1
N2 - BACKGROUND: The present analysis focuses on real-world data of Everolimus- Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years. METHODS: Data are collected from clinical records and analysed according to age cut-off (< 65 years; 65 - 69 years and [greater than or equal to] 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel- Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model. RESULTS: From July 2013 to December 2015, the EVA study enrolled overall 404 pts. 154 patients out of 404 (38,1%) were aged [greater than or equal to] 65 years, of whom 87 were [greater than or equal to] 70 years. Median duration of EVE treatment was 28.5 weeks (95% CI 19.0 - 33.8) in patients aged 65-69 years and 24,4 weeks (95% CI 19,2 - 33,2) in those aged [greater than or equal to] 70 years. Fewer patients aged 65 years received the highest EVE Dose-Intensity (> 7.5 mg/day) in comparison to younger patients (49,6% vs. 66,8%). Grade 3-4 toxicities occurred to 55 patients (35,7%), mainly stomatitis (10,9%), rash (5,8%) and non-infectious pneumonitis (NIP) (3,6%). Some toxicities, such as weight loss and anaemia were peculiarly observed in patients aged [greater than or equal to] 70 years. Five treatment-related deaths were collected (3,2%). CONCLUSIONS: EVE-EXE combination remains one of the potential treatments in HR+ patients also for elderly ones.
AB - BACKGROUND: The present analysis focuses on real-world data of Everolimus- Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years. METHODS: Data are collected from clinical records and analysed according to age cut-off (< 65 years; 65 - 69 years and [greater than or equal to] 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel- Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model. RESULTS: From July 2013 to December 2015, the EVA study enrolled overall 404 pts. 154 patients out of 404 (38,1%) were aged [greater than or equal to] 65 years, of whom 87 were [greater than or equal to] 70 years. Median duration of EVE treatment was 28.5 weeks (95% CI 19.0 - 33.8) in patients aged 65-69 years and 24,4 weeks (95% CI 19,2 - 33,2) in those aged [greater than or equal to] 70 years. Fewer patients aged 65 years received the highest EVE Dose-Intensity (> 7.5 mg/day) in comparison to younger patients (49,6% vs. 66,8%). Grade 3-4 toxicities occurred to 55 patients (35,7%), mainly stomatitis (10,9%), rash (5,8%) and non-infectious pneumonitis (NIP) (3,6%). Some toxicities, such as weight loss and anaemia were peculiarly observed in patients aged [greater than or equal to] 70 years. Five treatment-related deaths were collected (3,2%). CONCLUSIONS: EVE-EXE combination remains one of the potential treatments in HR+ patients also for elderly ones.
KW - Advanced breast cancer
KW - Elderly
KW - Everolimus
KW - Exemestane
KW - Hormone-receptor positive
UR - http://www.scopus.com/inward/record.url?scp=85054288051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054288051&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.25874
DO - 10.18632/oncotarget.25874
M3 - Article
AN - SCOPUS:85054288051
VL - 9
SP - 31877
EP - 31887
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 61
ER -